Molecular Docking for Chalcone Analogue Compounds as Inhibitor for Lung Cancer A549

  • Neni Frimayanti Sekolah Tinggi Ilmu Farmasi Riau
  • Meiriza Djohari Sekolah Tinggi Ilmu Farmasi Riau
  • Alifah Nurul Khusnah Sekolah Tinggi Ilmu Farmasi Riau
DOI: https://doi.org/10.35814/jifi.v19i1.765

Abstract

Chalcones are compounds derived from nature, it is show the anticancer activity. The aim of this
study is to determine the binding free energy (affi nity) and interaction of chalcone derivatives as inhibitors for A549 lung cancer cells using 4HFZ protein as receptors. This study used 10 chalcone derivatives which were selected with three lowest IC50 values, fi ve medium IC50 values and two with higher IC50 values (i.e. more than 100 μg/mL) and 4HFZ protein was used as receptor. The structure of the chalcone derivative is transformed in 3D structure, then the docking process of chalcone compounds with amino acids on the MDM2 receptor (4HFZ) is carried out. The simulation results shown that data in the form of binding free energy value (kcal / mol) shown the stability of ligand interaction of chalcone compounds on amino acids on MDM2 receptors. The docking results shown that, compound 2 is able to bind strongly with MDM2 receptor (4HFZ) and it is also stable because it has a low binding-free energy value of -7.2 kcal / mol, with a RMSD value of 0,000. Construction of some hydrogen bonds is the same as active receptor (gefi tinib), they are Leu54 on the NH2.

References

1. Corwin J. E. Buku Saku Patofi siologi Buku Kedokteran ECG. Edisi 3. Jakarta. 2009. p. 36-47

2. Siegel R. L, Miller D. K, Jemal A. Cancer Statistics. Cancer Journal for Clinicians, 2018. 67(1): 7-30.

3. Anonim. 2015. Situasi Penyakit Kanker. Departemen Kesehatan RI. Jakarta

4. Dipiro J, Talbert R, Yee G, Matzke G, Wells B. and Posey M, Pharmacotherapy: A Pathophysiologic Approach, Seventh Edition, The MC Graw Hill, New York. 2008.

5. Albogami A. S, Karama U, Mousa A. A, Khan M, Al-Mazroa S. A, dan Alkhathlan H. Z, Simple and Efficient One Step Synthesis of Functionalized Flavanones and Chalcones. Oriental Journal of Chemistry, 2012. 28(2): 619–26.

6. Jasril, Teruna H. Y, Zamri A, Alfatos D, Yuslinda Y, dan Nurulita Y. Sintesis dan Uji Antibakteri Senyawa
Bromo Kalkon Piridin. Jurnal Natur Indonesia, 2012. 14(3): 172–5.

7. Sulistyowaty M. I. K. A, Nofi anti K. A, and Budiati T. Invitro Antimalaria Activity of Chalcone and Its
Derivatives. Int. J. Pharm and Pharmaceutical sci, 2014. 6(1): 16–8.

8. Matsjeh S, Mustofa, Redjeki T, Wahyuningsih T. D, and Susanti V. H. E. Syntheses and Antioxidant
Activities of Some Hydroxy Dimethoxy Chalcone Derivatives. Ind. J. Pharm., 2013. 25(1): 17–24.

9. Suirta I. W. Sintesis Senyawa Kalkon Serta Uji Aktivitas Sebagai Antioksidan. Jurnal Kimia. 2016. : 75–80.

10. Hilma R, Jasril, Siregar S. H, dan Permana I. Aktivitas Antidiabetes Senyawa AnalogKalkon dan
Analog Kalkon (Subtituen Naftalen) Terhadap Enzim Α-Glukosidase. Jurnal Photon. 2015 (2): 233–238.

11. Berar U. Chalcones : Compounds Possessing a Diversity in Applications. Journal of Pharmacy
Research, 2012. 5(8): 4236–41.

12. Zamri A, Frimayanti N, and Teruna H. Y. Docking and Molecular Dynamic Simulations: Study of 1,3, 4-Oxadiazole- Chalcone Hybrid Derivatives to Search New Active Anticancer Agents. Thai J. Pharm Sci. 2016. 40(4): 179–84.

13. Pudjono, Sismindari, dan Widada H. Sintesis 2,5-bis-(4’-hidroksi benzilidin) siklopentanon dan
2,5-bis-(4’-klorobenzilidin) siklopentanon serta uji antiproliferatifnya terhadap sel HeLa. Majalah Farmasi Indonesia. 2008. 19(1): 48 – 55.

14. Mai C. W, Yaeghoobi M, Rahman A. N, Kang Y. B, and Pichika, M. R. Chalcones with Electron- Withdrawing and Electron-Donating Substituents: Anticancer Activity Against TRAIL Resistant Cancer Cells, Structure-Activity Relationship Analysis and Regulation of Apoptotic Proteins. Europ J Med. Chem. 2014. 77: 378–87.

15. Ramya T, Sathyanathan V, Praveen D, and Chowdhari C. M. Docking Studies on Synthesized Quinazoline
Compounds Against Androgen Receptor. Ind. J. Pharm, 2011. 1(4): 266–9.

16. Anonim. 2016. A549 (ATCC® CCL-185™) , Lung Carcinoma Cell Line. Diunduh tanggal 3 april 2018
pukul 12.00 dari https://www.atcc.org/en/Products/ All/CCL-185.aspx#characteristics.

17. Rohmah M. K. Studi In Silico Kompleks Ligand- Reseptor Eugenol Daun Basil (Ocimum basilicum
L.) dengan Reseptor Her2 pada Non-Small Cell Lung Cancer (Nsclc) dengan Kontrol Gefi tinib. J. of Pharm Res, 2017. 3(2): 71-8.

18. Zhao Y, Aguilar A, Bernard D, and Wang S. Small-Molecule Inhibitors of the MDM2 − p53 Protein − Protein Interaction ( MDM2 Inhibitors ) in Clinical Trials for Cancer Treatment. J. Med. Chem. 2015. 58: 1038−52.

19. Purnomo H. kimia komputasi untuk farmasi dan ilmu terkait: uji in sillico senyawa antikanker. Penerbit
Pustaka Pelajar. Yogyakarta. 2013

20. Negara B. A, dan Santoso B. Penilaian Hasil Molekuler Docking Analog Diketopiperazin Sebagai Inhibitor
Hiv-1 Protease. Naskah Publikasi UMS. 2014. 1(1): 1-10.

21. Monika G, Punam G, Sarbjot S, and Gupta G. D. An Overview on Molecular Docking. Int. J. Drug Develop
and Res. 2010. 2(2): 219–31.
Published
2021-04-30
How to Cite
FRIMAYANTI, Neni; DJOHARI, Meiriza; KHUSNAH, Alifah Nurul. Molecular Docking for Chalcone Analogue Compounds as Inhibitor for Lung Cancer A549. JURNAL ILMU KEFARMASIAN INDONESIA, [S.l.], v. 19, n. 1, p. 87-95, apr. 2021. ISSN 2614-6495. Available at: <http://jifi.farmasi.univpancasila.ac.id/index.php/jifi/article/view/765>. Date accessed: 22 dec. 2024. doi: https://doi.org/10.35814/jifi.v19i1.765.
Citation Formats
Issue
Vol 19 No 1 (2021): JIFI
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.

This licence applies to Author(s) and Public Reader means that the users mays :

  • SHARE:
    copy and redistribute the article in any medium or format
  • ADAPT:
    remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication)
  • ALIKE:
    If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original.
  • NO ADDITIONAL RESTRICTIONS:
    You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

It does however mean that when you use it you must:

  • ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

You may not:

  • NONCOMMERCIAL: You may not use the article for commercial purposes.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.